Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

Henk M. Lokhorst; Ingo Schmidt-Wolf; Pieter Sonneveld; Bronno van der Holt; Hans Martin; Rene Barge; Uta Bertsch; Jana Schlenzka; Gerard M. J. Bos; Sandra Croockewit; Sonja Zweegman; Iris Breitkreuz; Peter Joosten; Christof Scheid; Marinus van Marwijk-Kooy; Hans-Juergen Salwender; Marinus H. J. van Oers; Ron Schaafsma; Ralph Naumann; Harm Sinnige; Igor Blau; Gregor Verhoef; Okke de Weerdt; Pierre Wijermans; Shulamiet Wittebol; Ulrich Duersen; Edo Vellenga; Hartmut Goldschmidt; Pieter Sonneveldbronno Van Der Holt

doi:https://doi.org/10.3324/haematol.11644

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

Henk M. Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, Bronno van der Holt, Hans Martin, Rene Barge, Uta Bertsch, Jana Schlenzka, Gerard M. J. Bos, Sandra Croockewit, Sonja Zweegman, Iris Breitkreuz, Peter Joosten, Christof Scheid, Marinus van Marwijk-Kooy, Hans-Juergen Salwender, Marinus H. J. van Oers, Ron Schaafsma, Ralph Naumann, Harm SinnigeIgor Blau, Gregor Verhoef, Okke de Weerdt, Pierre Wijermans, Shulamiet Wittebol, Ulrich Duersen, Edo Vellenga, Hartmut Goldschmidt, Pieter Sonneveldbronno Van Der Holt

Research output: Contribution to journal › Article › Academic › peer-review

133 Citations (Scopus)

Abstract

In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p <0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p <0.001). CTC grade 3-4 adverse events were similar in both arms

Original language	English
Pages (from-to)	124-127
Number of pages	4
Journal	Haematologica
Volume	93
Issue number	1
DOIs	https://doi.org/10.3324/haematol.11644
Publication status	Published - Jan 2008

Keywords

Thalidomide
Untreated multiple myeloma

Access to Document

https://doi.org/10.3324/haematol.11644

http://www.mendeley.com/research/thalidomide-induction-treatment-increases-very-good-partial-response-rate-before-after-highdose-ther

Cite this

Lokhorst, H. M., Schmidt-Wolf, I., Sonneveld, P., van der Holt, B., Martin, H., Barge, R., Bertsch, U., Schlenzka, J., Bos, G. M. J., Croockewit, S., Zweegman, S., Breitkreuz, I., Joosten, P., Scheid, C., van Marwijk-Kooy, M., Salwender, H.-J., van Oers, M. H. J., Schaafsma, R., Naumann, R., ... Van Der Holt, P. S. (2008). Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica, 93(1), 124-127. https://doi.org/10.3324/haematol.11644

@article{ffa716618da844c0be494949cd503c71,

title = "Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma",

abstract = "In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p <0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p <0.001). CTC grade 3-4 adverse events were similar in both arms",

keywords = "Thalidomide, Untreated multiple myeloma",

author = "Lokhorst, {Henk M.} and Ingo Schmidt-Wolf and Pieter Sonneveld and {van der Holt}, Bronno and Hans Martin and Rene Barge and Uta Bertsch and Jana Schlenzka and Bos, {Gerard M. J.} and Sandra Croockewit and Sonja Zweegman and Iris Breitkreuz and Peter Joosten and Christof Scheid and {van Marwijk-Kooy}, Marinus and Hans-Juergen Salwender and {van Oers}, {Marinus H. J.} and Ron Schaafsma and Ralph Naumann and Harm Sinnige and Igor Blau and Gregor Verhoef and {de Weerdt}, Okke and Pierre Wijermans and Shulamiet Wittebol and Ulrich Duersen and Edo Vellenga and Hartmut Goldschmidt and {Van Der Holt}, {Pieter Sonneveldbronno}",

year = "2008",

month = jan,

doi = "https://doi.org/10.3324/haematol.11644",

language = "English",

volume = "93",

pages = "124--127",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "1",

}

Lokhorst, HM, Schmidt-Wolf, I, Sonneveld, P, van der Holt, B, Martin, H, Barge, R, Bertsch, U, Schlenzka, J, Bos, GMJ, Croockewit, S, Zweegman, S, Breitkreuz, I, Joosten, P, Scheid, C, van Marwijk-Kooy, M, Salwender, H-J, van Oers, MHJ, Schaafsma, R, Naumann, R, Sinnige, H, Blau, I, Verhoef, G, de Weerdt, O, Wijermans, P, Wittebol, S, Duersen, U, Vellenga, E, Goldschmidt, H & Van Der Holt, PS 2008, 'Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma', Haematologica, vol. 93, no. 1, pp. 124-127. https://doi.org/10.3324/haematol.11644

TY - JOUR

T1 - Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

AU - Lokhorst, Henk M.

AU - Schmidt-Wolf, Ingo

AU - Sonneveld, Pieter

AU - van der Holt, Bronno

AU - Martin, Hans

AU - Barge, Rene

AU - Bertsch, Uta

AU - Schlenzka, Jana

AU - Bos, Gerard M. J.

AU - Croockewit, Sandra

AU - Zweegman, Sonja

AU - Breitkreuz, Iris

AU - Joosten, Peter

AU - Scheid, Christof

AU - van Marwijk-Kooy, Marinus

AU - Salwender, Hans-Juergen

AU - van Oers, Marinus H. J.

AU - Schaafsma, Ron

AU - Naumann, Ralph

AU - Sinnige, Harm

AU - Blau, Igor

AU - Verhoef, Gregor

AU - de Weerdt, Okke

AU - Wijermans, Pierre

AU - Wittebol, Shulamiet

AU - Duersen, Ulrich

AU - Vellenga, Edo

AU - Goldschmidt, Hartmut

AU - Van Der Holt, Pieter Sonneveldbronno

PY - 2008/1

Y1 - 2008/1

N2 - In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p <0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p <0.001). CTC grade 3-4 adverse events were similar in both arms

AB - In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p <0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p <0.001). CTC grade 3-4 adverse events were similar in both arms

KW - Thalidomide

KW - Untreated multiple myeloma

U2 - https://doi.org/10.3324/haematol.11644

DO - https://doi.org/10.3324/haematol.11644

M3 - Article

C2 - 18166796

SN - 0390-6078

VL - 93

SP - 124

EP - 127

JO - Haematologica

JF - Haematologica

IS - 1

ER -